Eight-Year Surveillance of Uropathogenic Escherichia coli in Southwest China

Figures & data

Table 1 Trends of Antimicrobial Resistance Rate (%) in UPEC Isolates

Antibiotics	2012	2013	2014	2015	2016	2017	2018	2019	P-value	Trend
ESBL	59.3	62.5	57.8	59.2	51.9	51.5	52.8	49.7	0.003	↓
Ampicillin	90.6	86.9	88.2	87.3	87.5	85.9	83.8	85.8	0.013	↓
Cefoperazone/Sulbactam	NA	NA	NA	4.8	5.6	5.7	6.3	4.4	0.973	NS
Ampicillin/Sulbactam	56.3	53.5	56.5	59.1	54.8	46.9	44.4	42.8	0.013	↓
Piperacillin/Tazobactam	1.8	2	1.1	1.6	1.9	1.8	1.9	3.4	0.129	NS
Ceftazidime	31.9	30.3	26.3	28.9	27.9	28	28.7	26.1	0.069	NS
Ceftriaxone	66.8	65.4	59.7	61.9	60.3	56.2	56.5	54	<0.001	↓
Cefepime	22.3	22	18.4	20.1	21.4	19.8	17.8	26	0.783	NS
Cefoxitin	NA	NA	NA	11.8	11.1	11.2	11.8	12.5	0.295	NS
Aztreonam	43.7	43.1	38.4	40.8	39.1	40.1	40.3	39.6	0.105	NS
Ertapenem	0.5	1.3	1.4	1.5	1.7	1.1	1.5	1	0.481	NS
Imipenem	0	0.1	0.4	0.4	0.7	0.7	0.8	0.7	0.001	↑
Meropenem	NA	NA	NA	0.4	0.6	0.7	0.8	0.7	0.079	NS
Amikacin	2.3	4	2.1	3	1.8	2.1	2.5	1.5	0.174	NS
Gentamicin	51.2	50	49.2	46.5	42	41.9	38.5	28.6	0.001	↓
Tobramycin	18.4	17.3	15.5	17.1	15.3	13.9	12.7	15	0.011	↓
Ciprofloxacin	69.3	63.8	60.9	61.9	61.5	59.7	61.1	61.8	0.061	NS
Levofloxacin	66.6	60.4	58.5	58.1	56	55.8	58.5	59.4	0.113	NS
Trimethoprim/Sulfamethoxazole	64.8	59.6	56.5	58.5	64.5	52.6	47.9	51	0.028	↓
Nitrofurantoin	3.7	4	3.1	4.2	1.9	2.2	3.2	3.6	0.404	NS

Notes: ↑, resistance rate is increasing; ↓, resistance rate is decreasing; NS, not significant at the P < 0.05 value by the simple linear regression.

Abbreviation: NA, not available.

Table 2 The Comparison of Antimicrobial Susceptibility Profile Between ESBL-Producing and Non-ESBL-Producing Isolates

Antibiotics	ESBL (+)			ESBL (-)			P-value
	No. Tested	%(R)	%(S)	No. Tested	%(R)	%(S)
Ampicillin	4295	99.9	0.1	3418	71.0	26.6	<0.001
Cefoperazone/Sulbactam	2433	6.5	69.2	2154	4.0	91.9	<0.001
Ampicillin/Sulbactam	3762	69.2	11.7	2897	32.6	39.1	<0.001
Piperacillin/Tazobactam	4295	1.2	95.3	3418	2.9	94.1	<0.001
Ceftazidime	4295	44.9	52.3	3418	7.6	91.9	<0.001
Ceftriaxone	4295	99.0	0.9	3418	11.7	88.2	<0.001
Cefepime	4295	33.6	48.8	3418	4.9	94.1	<0.001
Cefoxitin	2307	11.3	80.1	2028	12.0	85.3	0.524
Aztreonam	4170	66.8	31.7	3317	7.5	92.0	<0.001
Ertapenem	4295	0.5	98.8	3418	2.2	97.2	<0.001
Imipenem	4295	0	100	3418	1.0	98.8	<0.001
Meropenem	2425	0	100	2147	1.3	98.7	<0.001
Amikacin	4137	3.5	96	3313	1.1	98.5	<0.001
Gentamicin	4070	51.7	47.2	3219	34.6	64.5	<0.001
Tobramycin	3888	22.4	45	3022	7.1	64.7	<0.001
Ciprofloxacin	4295	82.4	14.3	3418	49.9	43.8	<0.001
Levofloxacin	4295	77.1	6.3	3418	44.5	23.4	<0.001
Trimethoprim/Sulfamethoxazole	4012	64.4	35.6	3225	47.5	52.5	<0.001
Nitrofurantoin	3881	4.0	83.6	3018	2.1	90.7	<0.001

Abbreviations: ESBL (+), ESBL-producing isolates; ESBL (-), non-ESBL-producing isolates.

Table 3 Antimicrobial Susceptibility Profiles of 94 Uropathogenic CREC Isolates

Antibiotics	%R	%I	%S	%R 95% CI
Ampicillin	100	0	0	95.1–00
Cefoperazone/Sulbactam	81.4	13.5	5.1	68.7–89.9
Ampicillin/Sulbactam	98.8	1.2	0	92.7–99.9
Piperacillin/Tazobactam	51.1	26.6	22.3	40.6–61.5
Ceftazidime	98.9	0	1.1	93.3–99.9
Ceftriaxone	100	0	0	95.1–100
Cefepime	88.3	3.2 (SDD)	8.5	79.6–93.7
Cefoxitin	98.3	1.7	0	89.7–99.9
Aztreonam	89.3	1.1	9.6	80.9–94.5
Ertapenem	100	0	0	95.1–100
Imipenem	36.2	2.1	61.7	26.7–46.8
Meropenem	47.5	0	52.5	34.5–60.8
Amikacin	10.7	1.1	88.2	5.6–19.4
Gentamicin	62.6	3.3	34.1	51.8–72.3
Tobramycin	43.8	29.2	27	33.4–54.7
Ciprofloxacin	95.7	0	4.3	88.8–98.6
Levofloxacin	93.6	4.3	2.1	86.1–97.4
Trimethoprim/Sulfamethoxazole	69.2	0	30.8	58.5–78.2
Nitrofurantoin	9	19.1	71.9	4.2–17.4

Abbreviations: SDD, susceptible-dose dependent; CI, confidence interval.